Current Appointments & Affiliations
Associate Professor of Medicine
·
2021 - Present
Medicine, Pulmonary, Allergy, and Critical Care Medicine,
Medicine
Recent Publications
Predictors of Long-Term Survival in Patients with Idiopathic Pulmonary Fibrosis: Data from the IPF-PRO Registry.
Journal Article Lung · March 9, 2025 PURPOSE: We used data from the IPF-PRO Registry of patients with idiopathic pulmonary fibrosis (IPF) to identify characteristics that predicted survival for a further > 5 years. METHODS: Participants had IPF that was diagnosed or confirmed at the enrolling ... Full text Link to item CiteCough-Specific Quality of Life Predicts Disease Progression Among Patients With Interstitial Lung Disease: Data From the Pulmonary Fibrosis Foundation Patient Registry.
Journal Article Chest · September 2022 BACKGROUND: Cough is a common symptom of interstitial lung disease (ILD) and negatively impacts health-related quality of life (QOL). Previous studies have shown that among patients with idiopathic pulmonary fibrosis, cough may predict progression of lung ... Full text Link to item CiteProvider Perspectives on and Access to Palliative Care for Patients With Interstitial Lung Disease.
Conference Chest · August 2022 BACKGROUND: Interstitial lung disease (ILD) results in profound symptom burden and carries high mortality. Palliative care (PC) is dedicated to improving quality of life in patients with serious illness. Early PC provision improves rates of advance care pl ... Full text Link to item CiteRecent Grants
INS1009-311 PH ILD Pro00119035 A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter, Parallelgroup Study to Evaluate the Efficacy and Safety of Treprostinil Palmitil Inhalation Powder
Clinical TrialPrincipal Investigator · Awarded by Insmed · 2026 - 2030BI 1493-0002 Xe MRI
Clinical TrialPrincipal Investigator · Awarded by Boehringer Ingelheim Pharmaceuticals, Inc. · 2026 - 2030MTX-463-I201 Mediar Study -A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of MTX-463 in Participants with Idiopathic Pulmonary Fibrosis (IPF)
Clinical TrialPrincipal Investigator · Awarded by Mediar Therapeutics, Inc. · 2025 - 2030View All Grants
Education
University of Pennsylvania ·
1998
M.D.